Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 5,894 shares at $50.10 ($295K) on 2025-02-19, disclosed to the SEC on 2025-02-21.
Scheduled sale ($295k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.10 | 1,333 | $67K | 22.6% |
| 2 | $50.10 | 1,333 | $67K | 22.6% |
| 3 | $50.12 | 1,614 | $81K | 27.4% |
| 4 | $50.12 | 1,614 | $81K | 27.4% |
| Total | $50.11 avg | 5,894 | $295K | 100% |
| Filing → |
| PTCT | SELL | 2026-08-19 | $204K | — | Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |